# Terlipressin Administration in Septic Shock Refractory to Catecholamines

> **NCT00793559** · PHASE2 · UNKNOWN · sponsor: **Assaf-Harofeh Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- Septic Shock

## Interventions

- **DRUG:** terlipressin
- **DRUG:** terlipressin

## Key facts

- **NCT ID:** NCT00793559
- **Lead sponsor:** Assaf-Harofeh Medical Center
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-11
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2008-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00793559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00793559, "Terlipressin Administration in Septic Shock Refractory to Catecholamines". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00793559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*